ConductScience.org, home

Comparison · NCT00724854-65e8d2cc

Mono-infected With HCV vs Co-infected With HCV and HIV: Number of Participants With Rapid Virologic Response After 4 Weeks of Treatment

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Mono-infected With HCV vs Co-infected With HCV and HIV: Number of Participants With Rapid Virologic Response After 4 Weeks of Treatment. Trial comparisons, record NCT00724854-65e8d2cc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00724854-65e8d2cc

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.5460.5150.576wilson
Risk in group 20.4440.3350.559wilson
Risk difference, group 1 minus group 20.101-0.01770.214newcombe hybrid score
Risk ratio, group 1 over group 21.230.9421.6log
Odds ratio, group 1 over group 21.50.9282.43log
Number needed to treat, for one more participant with the outcome on Mono-infected With HCV than on Co-infected With HCV and HIV9.89from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Mono-infected With HCVParticipants infected with Hepatitis C Virus (HCV), received PegIntron plus Rebetol, administered in accordance with approved labeling.5511,010OG000
Group 2Co-infected With HCV and HIVParticipants co-infected with Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV), received PegIntron plus Rebetol, administered in accordance with approved labeling.3272OG001

Outcome

Type
PRIMARY
Title
Number of Participants With Rapid Virologic Response After 4 Weeks of Treatment
Description
Rapid virologic response (RVR) was defined as Hepatitis C Virus Ribonucleic acid (HCV RNA) negative after 4 weeks of treatment.
Time frame
Assessed at Treatment Week 4
Population

Source ClinicalTrials.gov

Trial

Title
Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)
NCT number
NCT00724854
Phases
Conditions
Hepatitis C, Chronic, Hepatitis C
Interventions
PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
Lead sponsor
Merck Sharp & Dohme LLC
Results first posted
2011-01-10

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00724854-65e8d2cc